100th patient enrolls in CartiHeal’s Agili-C IDE study: 5 insights

Principal investigator Elizaveta Kon, MD, PhD, of Humanitas Orthopedic Center of Milan, Italy, enrolled the 100th patient in CariHeal’s Agili-C Investigational Device Exemption pivotal study.

Advertisement

Here are five insights:

1. The newest patient suffers from an osteochondral defect in the center of the trochlea.

2. Dr. Kon said the patient was randomized into the Agili-C arm of the study and treated with a single implant.

3. This is Dr. Kon’s eighth patient in the study. She plans to enroll more in the future.

4. Agili-C has been implanted in more than 400 patients with cartilage lesions in the knee, ankle and big toe throughout centers in Europe and Israel.

5. The implant is designed to treat a broad spectrum of cartilage lesions, from single focal lesions and multiple and large defects in patients suffering from osteoarthritis.

More articles on devices and implants:
Bioventus appoints industry veteran to board of managers: 4 insights
3D printing, robotic surgery top Cleveland Clinic’s 2019 innovation list
Aurora Spine earns 1st European patent for minimally invasive spine implant

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.